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The Wilms' tumour suppressor gene, WT1, encodes
multiple nuclear protein isoforms, all containing four
C-terminal zinc ®nger motifs. WT1 proteins can both
activate and repress putative target genes in vitro,
although the in vivo relevance of these putative target
genes is often unveri®ed. WT1 mutations can result in
Wilms' tumour and the Denys-Drash Syndrome (DDS)
of infantile nephropathy, XY pseudohermaphroditism and
predisposition to Wilms' tumour. We have established
stable transfectants of the mouse mesonephric cell line,
M15, which express WT1 harbouring a common DDS
point mutation (R394W). A comparison of the expres-
sion pro®les of M15 and transfectant C2A was
performed using Nylon-based arrays. Very few genes
showed dierential expression. However Wnt-4, a
member of the Wnt gene family of secreted glycopro-
teins, was downregulated in C2A and other similar
clones. Doxycycline induction of WT1-A or WT1-D
expression in HEK293 stable transfectants also elicited
an elevation in Wnt4 expression. Wnt4 is critical for the
mesenchyme-to-epithelial transition during kidney devel-
opment, making it an attractive putative WT1 target.
We have mapped human Wnt-4 gene to chromosome
1p35-36, a region of frequent LOH in WT, have
characterized the genomic structure of the human Wnt-
4 gene and isolated 9 kb of immediate promoter. While
several potential WT1 binding sites exist within this
promoter, reporter analysis does not strongly support the
direct regulation of Wnt4 by WT1. We propose that
Wnt-4 regulation by WT1 occurs at a more distant
promoter or enhancer site, or is indirect.
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Introduction
Wilms' tumour (WT) or nephroblastoma is an
embryonal renal neoplasm aecting one out of 10 000
infants, thus accounting for about 6% of all childhood
malignancies (Matsunaga, 1981). The tumour charac-
teristically displays a triphasic histology consisting of
undierentiated blastemal stem cells, an epithelial
component, and ®broblastic stromal elements (Miller
et al., 1964). It is thought to arise from metanephric
blastemal cells that failed to properly dierentiate into
the epithelial components of the kidney, possibly due
to the inability of blastemal stem cells to respond to
normal dierentiation signals (Miller et al., 1964). WT
can occur in association with other congenital
anomalies, one of which is the WAGR syndrome of
Wilms' tumour, Aniridia (lack or defect of the iris),
Genitourinary anomalies, and mental Retardation. The
detection of cytogenetically detectable microdeletions
at chromosome position 11p13 in WAGR patients
(Francke et al., 1979) facilitated the positional cloning
of the WT suppressor gene, WT1 (Call et al., 1990;
Gessler et al., 1990). While numerous inactivating
mutations have been found in this gene in WT, the
percentage of WT cases with WT1 mutations is only
10 ± 15% (Little and Wells, 1997). WT show regions of
LOH at 11p13, but also on many other chromosomes,
including chromosomes 1p, 1q, 7p, 16q, and 17p
(Slater and Mannens, 1992). It is possible that these
loci represent other WT genes, which may lie up or
downstream of WT1. Constitutional heterozygous
WT1 mutations are also found in the congenital
anomaly of Denys-Drash syndrome (DDS) (XY
pseudohermaphroditism, mesangial sclerosis, and pre-
disposition to WT1) (Pelletier et al., 1991). The most
common of these, C1180T, occurs within exon 9 of
WT1 resulting in the substitution of arginine by
tryptophan (R394W) (Little and Wells, 1997).
The WT1 gene encodes multiple nuclear proteins by
virtue of three dierent transcription start sites, RNA
editing of a single nucleotide and two alternatively
spliced regions; exon 5 (17 amino acids) and an alternate
splice donor site after exon 9 (Haber et al., 1991; Sharma
et al., 1994; Bruening and Pelletier, 1996; Scharnhorst et
al., 1999). The latter results in the addition of three
amino acids (KTS) between exons 9 and 10. All isoforms
contain the four C-terminal zinc ®ngers. Taking the
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